Yorgin PD, Belson A, Sanchez J, Al Uzri AY, Sarwal M, Bloch DA, Oehlert J, Salvatierra O, Alexander SR (2002) Unexpectedly high prevalence of posttransplant anemia in pediatric and young adult renal transplant recipients. Am J Kidney Dis 40:1306–1318
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group (2012) KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279–335
Galutira PJ, Del Rio M (2012) Understanding renal post-transplantation anemia in the pediatric population. Pediatr Nephrol 27:1079–1085
Macdougall CI, Geisser P (2013) Use of intravenous iron supplementation in chronic kidney disease an update. Iran J Kidney Dis 7:9–22
Drüeke TB, Parfrey PS (2012) Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s). Kidney Int 82:952–960
Aksan A, Zepp F, Anand S, Stein J (2022) Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review. Eur J Pediatr 181:3781–3793
PubMed PubMed Central Google Scholar
Iorember F, Aviles D, Bamgbola O (2020) Impact of immediate post-transplant parenteral iron therapy on the prevalence of anemia and short-term allograft function in a cohort of pediatric and adolescent renal transplant recipients. Pediatr Transplant 24:e13787
Tan MLN, Windscheif PM, Thornton G, Gaynor E, Rodrigues A, Howarth L (2017) Retrospective review of effectiveness and safety of intravenous ferric carboxymaltose given to children with iron deficiency anaemia in one UK tertiary centre. Eur J Pediatr 176:1419–1423
Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W (2018) Randomized trial of intravenous iron-induced hypophosphatemia. JCI Insight 3:e124486
PubMed PubMed Central Google Scholar
Klein K, Asaad S, Econs M, Rubin JE (2018) Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration. BMJ Case Rep 2018:bcr-2017–222851
Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H (2021) Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis. Br J Clin Pharmacol 87:2256–2273
Kirk SE, Scheurer ME, Bernhardt MB, Mahoney DH, Powers JM (2021) Phosphorus levels in children treated with intravenous ferric carboxymaltose. Am J Hematol 96:E215–E218
PubMed PubMed Central CAS Google Scholar
Posod A, Schaefer B, Mueller T, Zoller H, Kiechl-Kohlendorfer U (2020) Hypophosphatemia in children treated with ferric carboxymaltose. Acta Paediatr 109:1491–1492
PubMed PubMed Central CAS Google Scholar
Laass MW, Straub S, Chainey S, Virgin G, Cushway T (2014) Effectiveness and safety of ferric carboxymaltose treatment in children and adolescents with inflammatory bowel disease and other gastrointestinal diseases. BMC Gastroenterol 14:184
PubMed PubMed Central Google Scholar
Carman N, Muir R, Lewindon P (2019) Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease. Transl Pediatr 8:28–34
PubMed PubMed Central Google Scholar
Papadopoulos M, Patel D, Korologou-Linden R, Goto E (2018) Safety and efficacy of parenteral iron in children with inflammatory bowel disease. Br J Clin Pharmacol 84:694–699
PubMed PubMed Central CAS Google Scholar
Garcia-Ortega P, Jimenez-Lozano I, Cruz Á, Polo AF, Lopez M, Ariceta G (2022) Safety and effectiveness of ferric carboxymaltose intravenous therapy in pediatric patients with chronic kidney disease. Front Pediatr 10:967233
PubMed PubMed Central Google Scholar
Guzzo I, Atkinson MA (2023) Anemia after kidney transplantation. Pediatr Nephrol 38:3265–3273
(2021) Ferinject (ferric carboxymaltose) summary of product characteristics. https://www.medicines.org.uk/emc/product/5910/smpc. Accessed May 2022
(2022) Injectafer prescribing information. https://injectafer.com/. Accessed May 2022
Comments (0)